National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.
By T. Jacobson, Matthew K. Ito, K. Maki, C. Orringer, H. Bays, Peter H. Jones, J. Mckenney, S. Grundy, E. Gill, R. Wild and 2 more. Journal of Clinical Lipidology, 2015
718 citations recorded by the source corpus.
Subfields: Economics and Econometrics, Endocrinology, Diabetes and Metabolism, Surgery
View Paper: https://www.semanticscholar.org/paper/24b92e157bbc7a4ab951b51a7895c1512ee00fcf
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Economics and Econometrics
In Endocrinology, Diabetes and Metabolism
In Surgery
Citations in the corpus
- Metabolic syndrome update. (2016, background): “In secondary prevention, it is reasonable to reduce non-HDL-C to o100 mg/dL; in primary prevention, a reasonable goal is o130 mg/dL [85].”
- National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. (2015, methodology): “The focus of the evidence summarized below is on the influence of lifestyle interventions on lipoprotein lipid levels, but clinicians should be aware that changes in other risk factors contribute to ASCVD risk.(1) Limited evidence is available from randomized clinical trials to assess the impacts of”